GlassScriptPhysician profile
Alexander Kosenko
NPI 1356386817
$2,239.78
in general payments reported to CMS, 2019-2025
25 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $475 · 2021: $497 · 2022: $186 · 2023: $274 · 2024: $251 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.38 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $274.64 | 2019-2021 | |
| Amgen INC. | $255.38 | 2019-2024 | Aranesp, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $247.04 | 2019-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $240.79 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $147.69 | 2019-2021 | |
| Horizon Therapeutics Plc | $125.47 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $100.69 | 2020-2025 | Vafseo |
| Novartis Pharmaceuticals Corporation | $94.97 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.77 | 2020-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $84.79 | 2019-2024 | Velphoro |
| Glaxosmithkline, LLC. | $75.30 | 2021-2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $73.36 | 2019 | |
| Alexion Pharmaceuticals, INC. | $71.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.20 | 2022-2024 | |
| Travere Therapeutics, INC. | $62.86 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $40.06 | 2021-2022 | |
| Lilly USA, LLC | $27.96 | 2024 | Jardiance |
| Nxstage Medical, INC. | $26.62 | 2020 | |
| Aurinia Pharma U.S., INC. | $25.28 | 2021 | |
| Recor Medical INC | $22.93 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ani Pharmaceuticals, INC. | $21.27 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $16.88 | 2021 | |
| Ardelyx, INC. | $15.16 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kosenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.